BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 22380774)

  • 1. Topoisomerase as target for antibacterial and anticancer drug discovery.
    Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
    J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerases as anticancer targets.
    Delgado JL; Hsieh CM; Chan NL; Hiasa H
    Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
    Kathiravan MK; Kale AN; Nilewar S
    Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
    Tse-Dinh YC
    Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrroloquinolinone-based dual topoisomerase I/II inhibitor.
    Dalla Via L; Marzaro G; Ferrarese A; Gia O; Chilin A
    Eur J Med Chem; 2014 Apr; 77():103-9. PubMed ID: 24631729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
    You F; Gao C
    Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase inhibitors as anticancer agents: a patent update.
    Khadka DB; Cho WJ
    Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.
    Liang X; Wu Q; Luan S; Yin Z; He C; Yin L; Zou Y; Yuan Z; Li L; Song X; He M; Lv C; Zhang W
    Eur J Med Chem; 2019 Jun; 171():129-168. PubMed ID: 30917303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives.
    Wang YC; Qian C; Peng ZL; Hou XJ; Wang LL; Chao H; Ji LN
    J Inorg Biochem; 2014 Jan; 130():15-27. PubMed ID: 24145066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases.
    Casu L; Cottiglia F; Leonti M; De Logu A; Agus E; Tse-Dinh YC; Lombardo V; Sissi C
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7041-4. PubMed ID: 22014547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of N-substituted benzo[c]phenanthrolines and benzo[c]phenanthrolinones as antiproliferative agents.
    Genès C; Lenglet G; Depauw S; Nhili R; Prado S; David-Cordonnier MH; Michel S; Tillequin F; Porée FH
    Eur J Med Chem; 2011 Jun; 46(6):2117-31. PubMed ID: 21435753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
    Ehmann DE; Lahiri SD
    Curr Opin Pharmacol; 2014 Oct; 18():76-83. PubMed ID: 25271174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugging topoisomerases: lessons and challenges.
    Pommier Y
    ACS Chem Biol; 2013 Jan; 8(1):82-95. PubMed ID: 23259582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
    Basarab GS; Manchester JI; Bist S; Boriack-Sjodin PA; Dangel B; Illingworth R; Sherer BA; Sriram S; Uria-Nickelsen M; Eakin AE
    J Med Chem; 2013 Nov; 56(21):8712-35. PubMed ID: 24098982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activities of topopyrones.
    Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
    J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I/II inhibition by a novel naphthoquinone containing a modified anthracycline ring system.
    Kennedy S; DiCesare JC; Sheaff RJ
    Biochem Biophys Res Commun; 2011 Apr; 408(1):94-8. PubMed ID: 21458415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.
    Sanyal G; Doig P
    Expert Opin Drug Discov; 2012 Apr; 7(4):327-39. PubMed ID: 22458504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.